Prevalence of drug resistance-associated gene mutations in plasmodium vivax in central china

Korean Journal of Parasitology

Volumn 50, Issue 4, 2012, Pages 379-384

  Lu, Feng ^a,b   Wang, Bo ^a   Cao, Jun ^b   Sattabongkot, Jetsumon ^c   Zhou, Huayun ^b   Zhu, Guoding ^b   Kim, Kwonkee ^d   Gao, Qi ^b   Han, Eun Taek ^a  

^a Kangwon National University   (South Korea)

^b BEIJING HOSPITAL   (China)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Gachon University College of Medicine   (South Korea)

Author keywords

Central china; Drug resistance; Mutation; Plasmodium vivax

Indexed keywords

CHLOROQUINE; CHLOROQUINE PLUS PRIMAQUINE; PROTOZOAL PROTEIN; PUTATIVE TRANSPORTER PROTEIN CG10; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; FOLIC ACID ANTAGONIST; PROTOZOAL DNA;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CHINA; GENE; GENE ACTIVITY; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE ISOLATION; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PREVALENCE; PROTOZOAL GENETICS; PVCRT O GENE; PVDHFR GENE; PVDHPS GENE; PVMDR1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; CHEMISTRY; DNA SEQUENCE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; GENOTYPE; HUMAN; ISOLATION AND PURIFICATION; MALARIA, VIVAX; PARASITOLOGY; POINT MUTATION;

ANTIMALARIALS; CHINA; CHLOROQUINE; DNA, PROTOZOAN; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; GENOTYPE; HUMANS; MALARIA, VIVAX; PLASMODIUM VIVAX; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROTOZOAN PROTEINS; SEQUENCE ANALYSIS, DNA; TANDEM REPEAT SEQUENCES;

EID: 84870851841     PISSN: 00234001     EISSN: 17380006     Source Type: Journal    
DOI: 10.3347/kjp.2012.50.4.379     Document Type: Article

References (34)

1. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol 2009; 25: 220-227.
2. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 2009; 9: 555-566.
3. Zhou SS, Wang Y, Tang LH. Malaria situation in the People's Re-public of China in 2006. Chinese J Parasitol Parasit Dis 2007; 25: 439-441 (in Chinese).
4. Lu F, Gao Q, Chotivanich K, Xia H, Cao J, Udomsangpetch R, Cui L, Sattabongkot J. In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China. Am J Trop Med Hyg 2011; 85: 197-201.
5. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, Prasetyorini B, Piera KA, Barends M, Brockman A, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN. Chloroquine resistant Plasmodium vivax: In vitro characteri- sation and association with molecular polymorphisms. PLoS One 2007; 2: e1089.
6. Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, Sutanto I, Peyron F, Picot S. Identifcation of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single nucleotide polymorphisms among isolates from different areas of endemicity. J Infect Dis 2005; 191: 272-277.
7. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic effcacies of artesunate-sulfadoxine-pyrimethamine and chloro- quine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: Relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 2002; 46: 3947-3953.
8. de Pécoulas PE, Tahar R, Ouatas T, Mazabraud A, Basco LK. Sequence variations in the Plasmodium vivax dihydrofolate reduc- tase-thymidylate synthase gene and their relationship with pyri- methamine resistance. Mol Biochem Parasitol 1998; 92: 265-273.
9. Imwong M, Pukrittakayamee S, Looareesuwan S, Pasvol G, Poirreiz J, White NJ, Snounou G. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimeth- amine: geographical and clinical correlates. Antimicrob Agents Chemother 2001; 45: 3122-3127.
10. Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K, Cheng Q. Sulfadoxine resistance in Plasmodium vivax is associated with a specifc amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob Agents Chemother 2004; 48: 2214-2222.
11. Phillips EJ, Keystone JS, Kain KC. Failure of combined chloro- quine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis 1996; 23: 1171-1173.
12. Imwong M, Pukrittayakamee S, Cheng Q, Moore C, Looareesuwan S, Snounou G, White NJ, Day NP. Limited polymorphism in the dihydropteroate synthetase gene (dhps) of Plasmodium vivax isolates from Thailand. Antimicrob Agents Chemother 2005; 49: 4393-4395.
13. Marfurt J, de Monbrison F, Brega S, Barbollat L, Müller I, Sie A, Goroti M, Reeder JC, Beck HP, Picot S, Genton B. Molecular mar- kers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis 2008; 198: 409-417.
14. Sá JM, Nomura T, Neves J, Baird JK, Wellems TE, del Portillo HA. Plasmodium vivax: allele variants of the mdr1 gene do not associ- ate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp Parasitol 2005; 109: 256-259.
15. Nomura T, Carlton JM, Baird JK, del Portillo HA, Fryauff DJ, Rathore D, Fidock DA, Su X, Collins WE, McCutchan TF, Wootton JC, Wellems TE. Evidence for different mechanisms of chloro quine resistance in 2 Plasmodium species that cause human ma- laria. J Infect Dis 2001; 183: 1653-1661.
16. Lu F, Gao Q, Zhou H, Cao J, Wang W, Lim CS, Na S, Tsuboi T, Han ET. Molecular test for vivax malaria with loop-mediated iso- thermal amplification method in central China. Parasitol Res 2012; 110: 2439-2444.
17. Miao M, Yang Z, Cui L, Ahlum J, Huang Y. Different allele preva- lence in the dihydrofolate reductase and dihydropteroate syn- thase genes in Plasmodium vivax populations from China. Am J Trop Med Hyg 2010; 83: 1206-1211.
18. Chen JS, Zhang KR, Geng ZW. Clinical observation on the in vivo sensitivity of Plasmodium vivax to pyrimethamine in Kaifeng District, Henan Province. Henan J Prev Med 1977; 51-56 (in Chinese).
19. Shen JQ, Hu XS. Comparison of effcacy between long-term oral administration of pyrimethamine and antimalarial pill 3. Rail- way Med J 1978; 2: 90-91 (in Chinese).
20. Hastings MD, Sibley CH. Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proc Natl Acad Sci USA 2002; 99: 13137-13141.
21. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH. Antifolates can have a role in the treatment of Plasmodi- um vivax. Trends Parasitol 2007; 23: 213-222.
22. Yang XM, Yang MQ, Huang JW. Clinical research of the sensitivi- ty of Plasmodium vivax to chloroquine. Chinese J Parasitol Parasit Dis 1996; 9: 226-227 (in Chinese).
23. Imwong M, Pukrittayakamee S, Pongtavornpinyo W, Nakeesathit S, Nair S, Newton P, Nosten F, Anderson TJ, Dondorp A, Day NP, White NJ. Gene amplifcation of the multidrug resistance 1 gene of Plasmodium vivax isolates from Thailand, Laos, and Myan- mar. Antimicrob Agents Chemother 2008; 52: 2657-2659.
24. Hastings MD, Maguire JD, Bangs MJ, Zimmerman PA, Reeder JC, Baird JK, Sibley CH. Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system. Antimicrob Agents Chemother 2005; 49: 733-740.
25. Auliff A, Wilson DW, Russell B, Gao Q, Chen N, Anh le N, Maguire J, Bell D, O'Neil MT, Cheng Q. Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical re- gions and susceptibility to antifolate drugs. Am J Trop Med Hyg 2006; 75: 617-621.
26. Rungsihirunrat K, Nabangchang K, Hawkins VN, Mungthin M, Sibley CH. Sensitivity to antifolates and genetic analysis of Plasmodium vivax isolates from Thailand. Am J Trop Med Hyg 2007; 76: 1057-1065.
27. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ, Sibley CH, Baird JK. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J Infect Dis 2004; 189: 744-750.
28. Lu F, Lim CS, Nam DH, Kim K, Lin K, Kim TS, Lee HW, Chen JH, Wang Y, Sattabongkot J, Han ET. Mutations in the antifolate- resistance-associated genes dihydrofolate reductase and dihy- dropteroate synthase in Plasmodium vivax isolates from malaria- endemic countries. Am J Trop Med Hyg 2010; 83: 474-479.
29. Brega S, de Monbrison F, Severini C, Udomsangpetch R, Sutanto I, Ruckert P, Peyron F, Picot S. Real-time PCR for dihydrofolate reductase gene single-nucleotide polymorphisms in Plasmodium vivax isolates. Antimicrob Agents Chemother 2004; 48: 2581-2587.
30. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM. Pyrimeth- amine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 2001; 17: 582-588.
31. Menegon M, Majori G, Severini C. Genetic variations of the Plas- modium vivax dihydropteroate synthase gene. Acta Trop 2006; 98: 196-199.
32. Hawkins VN, Suzuki SM, Rungsihirunrat K, Hapuarachchi HC, Maestre A, Na-Bangchang K, Sibley CH. Assessment of the ori- gins and spread of putative resistance-conferring mutations in Plasmodium vivax dihydropteroate synthase. Am J Trop Med Hyg 2009; 81: 348-355.
33. Lu F, Lim CS, Nam DH, Kim K, Lin K, Kim TS, Lee HW, Chen JH, Wang Y, Sattabongkot J, Han ET. Genetic polymorphism in pvmdr1 and pvcrt-o genes in relation to in vitro drug susceptibili- ty of Plasmodium vivax isolates from malaria-endemic countries. Acta Trop 2011; 117: 69-75.
34. Huang F, Zhou S, Zhang S, Li W, Zhang H. Monitoring resistance of Plasmodium vivax: point mutations in dihydrofolate reductase gene in isolates from Central China. Parasit Vectors 2011; 4: 80.